환자 유래 이종 이식 모델 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Patient-Derived Xenograft Model Market size is expected to reach USD 799.97 Million in 2034 from USD 335.13 Million (2025) growing at a CAGR of 10.15% during 2026-2034.

The Global Patient-Derived Xenograft (PDX) Model Market is growing steadily as pharmaceutical and biotechnology companies focus more on personalized medicine. PDX models are created by implanting human tumor tissues into immunodeficient mice, which helps researchers study cancer behavior more accurately. The rising number of cancer cases worldwide and the demand for effective targeted therapies are major factors supporting market growth. In addition, increasing investment in oncology research and drug discovery programs is boosting the use of PDX models.

One of the key drivers of this market is the growing need for reliable preclinical models that closely replicate human tumor biology. Traditional cell-line models often fail to predict clinical outcomes accurately, whereas PDX models provide better insights into drug response. The expansion of precision medicine initiatives and collaborations between academic institutions and pharmaceutical companies are also contributing to demand. Government funding for cancer research further supports the development and adoption of advanced research models.

In the coming years, the market is expected to expand with advancements in humanized mouse models and improved transplantation techniques. The integration of genomic profiling and biomarker analysis with PDX platforms will enhance their value in drug development. Emerging markets are also likely to witness growth due to increasing healthcare investments. Overall, continuous innovation and strong focus on oncology research will create promising future opportunities for this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Tumor Type

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Others

By Model Type

• Mice Model
• Rat Model

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• CROs and CDMOs

COMPANIES PROFILED

• Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY TUMOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Tumor Type
• 4.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY MODEL TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Model Type
• 5.2. Mice Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Rat Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CROs and CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Tumor Type
  • 7.2.2 By Model Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Tumor Type
  • 7.3.2 By Model Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Tumor Type
  • 7.4.2 By Model Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Tumor Type
  • 7.5.2 By Model Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Tumor Type
  • 7.6.2 By Model Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PATIENT-DERIVED XENOGRAFT MODEL INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Charles River Laboratories
  • 9.2.2 The Jackson Laboratory
  • 9.2.3 Crown Bioscience
  • 9.2.4 Altogen Labs
  • 9.2.5 Envigo
  • 9.2.6 WuXi AppTec
  • 9.2.7 Oncodesign
  • 9.2.8 Hera Biolabs
  • 9.2.9 XenTech
  • 9.2.10 Abnova Corp